After a brutal correction, several leading biotech members of the IBD 50 found support at their 50-day moving averages. The correction kicked off Monday when Express Scripts (ESRX), the nation’s largest health benefits manager, announced that it would exclusively use AbbVie’s (ABBV) hepatitis C drug. That left Gilead Sciences (GILD), whose recent growth has been fueled by its hepatitis C treatment, out of the picture.